You can read the full November 22 print issue of Chain Drug Review in its entirety here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!
With our iA customers, we see how pharmacy providers are increasingly competing to offer the best experience to attract and retain patients and customers. An important aspect of this commitment is spending time with patients and giving patients the choice of when, where and how they receive their prescriptions. The introduction of therapy management solutions
Scientists researched, developed and tested COVID-19 vaccines in record time — then the race to manufacture and deliver them to health care sites around the world began. To save lives, the vaccination program was rapidly rolled out. On the front line, pharmacists, nurses and doctors worked day and night to vaccinate the most vulnerable patients
It has been a big fall for interchangeable biologics. President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” directed the Department of Health and Human Services (and the Food and Drug Administration), and HHS subsequently published its “Comprehensive Plan for Addressing High Drug Prices.” Interchangeable biosimilars are front and center in both of
Like many other policies intended to curb the spread of COVID-19, the Biden administration’s emergency temporary standard (ETS), which requires companies with 100 or more employees to ensure that members of their workforce are immunized or undergo weekly testing, has become a flashpoint. In addition to expected resistance from many Republicans, some business groups, including
This newspaper has no more committed — and significant — supporter than Scott Emerson. To those few in our retail audience who, unfortunately for them, have not yet taken advantage of the many benefits Emerson has to offer, some background information is in order. Scott Emerson is the founder, chief executive and primary motivator of
